Your session is about to expire
β Back to Search
Descartes-08 for Myasthenia Gravis
Study Summary
This trial is testing a new treatment for Myasthenia Gravis, a disease that causes muscle weakness.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check βYesβ for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- People who test negative for certain antibodies are allowed to participate.I have been diagnosed with Generalized Myasthenia Gravis.I have been diagnosed with Generalized Myasthenia Gravis.I am 18 years old or older.You are taking other medications that lower your immune system, but only if your doctor thinks it's necessary.I am 18 years old or older.
- Group 1: Phase IIb Randomized Control Trial
- Group 2: Phase IIa Expansion
- Group 3: Phase 1b Dose-Escalation
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there restrictions on the number of participants who can join this clinical research?
"This research endeavour requires 30 participants who meet the pre-defined qualifications. Eligible patients can partake in this experiment at University of Miami, situated in Florida or University of Augusta found in Georgia."
Is enrollment currently open for this experiment?
"According to the clinicaltrials.gov website, this medical trial remains open and is now accepting applicants. The details of the study were first posted on December 4th 2019 and have since been updated as recently as November 18th 2022."
What is the purpose of this clinical experiment?
"This clinical trial, with an assessment period of 28 days, endeavors to assess the impact of Myasthenia gravis -Activities of Daily Living Score. Secondary objectives include analyzing Descartes-08's efficacy versus placebo on QMG, MG QoL 15R, MG Composite and MG PIS (change from baseline to Week 12) in all randomized patients; comparing crossover patients who transitioned from placebo to Descartes-08 on corresponding assessments over a similar time frame; and evaluating single or multiple infusions of Descartes-08 by standard clinical scales for both autoantibody seropositive and negative subjects over"
What deleterious impacts could Descartes-08 have on patient health?
"Descartes-08 is deemed moderately safe by the evaluation team at Power because this Phase 2 trial has only showcased data of its safety, not efficacy. Thus it was awarded a score of two."
What is the geographic range of this trial's implementation?
"This trial is still enrolling participants across 13 sites, including Miami, Augusta and Pittsburgh. It's prudent to choose the closest location possible in order to minimize travel demands if you decide to take part."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger